MyChart is not for medical emergencies. If you have a medical emergency, call 911.
If you need help with MyChart, call us at 1-844-442-4278
Cancers of the blood (hematologic malignancies) affect the bone marrow, blood cells, lymph nodes and other parts of the lymphatic system. Malignancies in the blood interfere with normal blood cell production or function. As the cancer cells multiply, they stop your blood from performing essential functions such as fighting off infection.
Decades of scientific research and clinical trials have led to more effective treatments and better outcomes for the more than 150,000 people diagnosed with blood cancers each year. At the University of Chicago Medicine, we’re at the forefront of leading-edge research, the latest clinical trials and the newest treatments for leukemia, lymphoma and multiple myeloma.
We care for more than 300 patients with leukemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) each year, making our program one of the largest in Chicago.
We are at the forefront of developing new therapies for Hodgkin and non-Hodgkin lymphomas, bringing the newest treatments to our patients as soon as they are available.
New medications, targeted therapies and cellular therapies have changed the landscape for patients with multiple myeloma. UChicago Medicine offers all of the latest treatments for this complex condition.
We are really focused on developing new therapies and new approaches to this disease. And we do this mostly through our clinical trials. And we have one of the largest number of clinical trials not only in the region, but probably in the nation. And over the last year, we've accrued over 1,000 patients to cancer clinical trials.
CAR T-cell therapy supercharges a patient's white blood cells to seek out and destroy cancer cells. Research at UChicago Medicine played a key role in the development of this exciting new immunotherapy.View videos and learn more